Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | TSHR | P16473 | 3/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 2/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | TDP2 | O95551 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10121051 | 1.00 | LMNA (0.36) | LMNAMAPK1ALDH1A1TSHRPOLB | |
| SCHEMBL867438 | 0.83 | LMNA (0.37) | LMNAMAPK1ALDH1A1TSHRPOLB | |
| SCHEMBL10121119 | 0.83 | LMNA (0.37) | LMNAMAPK1ALDH1A1TSHRPOLB | |
| SCHEMBL868915 | 0.83 | LMNA (0.37) | LMNAMAPK1ALDH1A1TSHRPOLB | |
| SCHEMBL10121076 | 0.83 | LMNA (0.37) | LMNAMAPK1ALDH1A1TSHRPOLB | |
| SCHEMBL15822613 | 0.82 | LMNA (0.35) | LMNAMAPK1ALDH1A1TSHRPOLB | |
| SCHEMBL417001 | 0.81 | LMNA (0.36) | LMNAMAPK1ALDH1A1TSHRPOLB | |
| SCHEMBL10195060 | 0.81 | LMNA (0.36) | LMNAMAPK1ALDH1A1TSHRPOLB | |
| SCHEMBL13042007 | 0.78 | LMNA (0.33) | LMNAMAPK1TSHRHPGDSMN1; SMN2 | |
| SCHEMBL13042005 | 0.78 | LMNA (0.33) | LMNAMAPK1TSHRHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8987476-B2 | Spiro epoxides as intermediates | SYNGENTA LIMITED (GB) | 2015-03-24 | — | — | US | disclosed |
| US-8987476-B2 | Spiro epoxides as intermediates | SYNGENTA LIMITED (GB) | 2015-03-24 | — | — | US | disclosed |
| US-8987476-B2 | Spiro epoxides as intermediates | SYNGENTA LIMITED (GB) | 2015-03-24 | — | — | US | disclosed |
| US-20140135508-A1 | SPIRO EPOXIDES AS INTERMEDIATES | SYNGENTA LIMITED (GB) | 2014-05-15 | — | — | US | disclosed |
| US-20140135508-A1 | SPIRO EPOXIDES AS INTERMEDIATES | SYNGENTA LIMITED (GB) | 2014-05-15 | — | — | US | disclosed |
| US-20140135508-A1 | SPIRO EPOXIDES AS INTERMEDIATES | SYNGENTA LIMITED (GB) | 2014-05-15 | — | — | US | disclosed |
| US-8680299-B2 | Spiro epoxides as intermediates | SYNGENTA LIMITED (GB) | 2014-03-25 | — | — | US | disclosed |
| US-8680299-B2 | Spiro epoxides as intermediates | SYNGENTA LIMITED (GB) | 2014-03-25 | — | — | US | disclosed |
| US-8680299-B2 | Spiro epoxides as intermediates | SYNGENTA LIMITED (GB) | 2014-03-25 | — | — | US | disclosed |
| US-20120077993-A1 | SPIRO EPOXIDES AS INTERMEDIATES | SYNGENTA CROP PROTECTION, LLC (US) | 2012-03-29 | — | — | US | disclosed |
| US-20120077993-A1 | SPIRO EPOXIDES AS INTERMEDIATES | SYNGENTA CROP PROTECTION, LLC (US) | 2012-03-29 | — | — | US | disclosed |
| US-20120077993-A1 | SPIRO EPOXIDES AS INTERMEDIATES | SYNGENTA CROP PROTECTION, LLC (US) | 2012-03-29 | — | — | US | disclosed |
| WO-2010136431-A9 | SPIRO EPOXIDES AS INTERMEDIATES | SYNGENTA LIMITED (GB) | 2011-03-10 | — | — | WO | disclosed |
| WO-2010136431-A1 | SPIRO EPOXIDES AS INTERMEDIATES | SYNGENTA LIMITED (GB) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077993-A1 | SPIRO EPOXIDES AS INTERMEDIATES | CYP1A1, CYP2E1, CYP1B1 | LMNA 2623/4885MAPK1 1464/4885ALDH1A1 39/4885 |
| US-20140135508-A1 | SPIRO EPOXIDES AS INTERMEDIATES | CYP1A1, CYP2E1, GSTO1 | LMNA 2914/4885MAPK1 1509/4885ALDH1A1 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.